009300 — Sam-A Pharm Co Income Statement
0.000.00%
- KR₩104bn
- KR₩48bn
- KR₩96bn
Annual income statement for Sam-A Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 53,653 | 54,666 | 81,700 | 97,211 | 95,581 |
Cost of Revenue | |||||
Gross Profit | 32,370 | 32,658 | 50,163 | 61,624 | 60,828 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 49,722 | 48,618 | 63,446 | 73,711 | 71,114 |
Operating Profit | 3,930 | 6,048 | 18,253 | 23,500 | 24,466 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,573 | 5,335 | 18,400 | 28,476 | 29,270 |
Provision for Income Taxes | |||||
Net Income After Taxes | 124 | 3,392 | 11,912 | 21,374 | 22,080 |
Net Income Before Extraordinary Items | |||||
Net Income | 124 | 3,392 | 11,912 | 21,374 | 22,080 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 124 | 3,392 | 11,912 | 21,374 | 22,080 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.01 | 521 | 1,953 | 3,481 | 3,618 |
Dividends per Share |